FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alan Giles

Research Profile

Chemicals & Drugs

Disorders

Phenomena

Co-author Network

Publications

TOP 3
Cheng Hock Toh; Lawrence O Ticknor; Colin Downey; Alan Giles; Ray C Paton; Richard Wenstone
Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation.
Michael E Nesheim; John Samis; John Walker; Lev Becker; Nicole Brufatto; Timothy Fischer; Liliana Tejidor; Greg Jones; Wim Houdijk; Alan Giles; Marlys L Koschinsky; Richard Wenstone; Colin Downey; Cheng Hock Toh
Lipoprotein-complexed C-reactive protein and the biphasic transmittance waveform in critically ill patients.
Cheng Hock Toh; Alan Giles
Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alan Giles (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2003: Cheng Hock Toh; Lawrence O Ticknor; Colin Downey; Alan Giles; Ray C Paton; Richard Wenstone
Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation.
Intensive care medicine 2003;29(1):55-61.
2002: Michael E Nesheim; John Samis; John Walker; Lev Becker; Nicole Brufatto; Timothy Fischer; Liliana Tejidor; Greg Jones; Wim Houdijk; Alan Giles; Marlys L Koschinsky; Richard Wenstone; Colin Downey; Cheng Hock Toh
Lipoprotein-complexed C-reactive protein and the biphasic transmittance waveform in critically ill patients.
Blood reviews 2002;16 Suppl 1():S15-22.
2002: Cheng Hock Toh; Alan Giles
Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC).
Clinical and laboratory haematology 2002;24(6):321-7.
2002: Cheng Hock Toh; John Samis; Colin Downey; John Walker; Lev Becker; Nicole Brufatto; Liliana Tejidor; Greg Jones; Wim Houdijk; Alan Giles; Marlys L Koschinsky; Lawrence O Ticknor; Ray Paton; Richard Wenstone; Michael E Nesheim
Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation.
Blood 2002;100(7):2522-9.
2002: Bert Verbruggen; Waander L van Heerde; Irena Novákovà; David Lillicrap; Alan Giles
A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay.
Thrombosis and haemostasis 2002;88(2):362-4.
2002: Christine Hough; Seiki Kamisue; Cherie Cameron; Colleen Notley; Shawn Tinlin; Alan Giles; David Lillicrap
Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia.
Thrombosis and haemostasis 2002;87(4):659-65.
2001: Bert Verbruggen; Alan Giles; John Samis; K Verbeek; E Mensink; I Novákovà
The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.
Thrombosis and haemostasis 2001;86(6):1435-9.
2000: JC Ribau; John Samis; Yotis A Senis; D H Maurice; Alan Giles; M DeReske; P Marlene Absher; Mark W C Hatton; Mary Richardson
Aortic endothelial cell von Willebrand factor content, and circulating plasminogen activator inhibitor-1 are increased, but expression of endothelial leukocyte adhesion molecules is unchanged in insulin-dependent diabetic BB rats.
Atherosclerosis 2000;149(2):331-42.
2000: John Samis; G D Ramsey; John B Walker; Michael E Nesheim; Alan Giles
Proteolytic processing of human coagulation factor IX by plasmin.
Blood 2000;95(3):943-51.
1998: John Samis; E Kam; Michael E Nesheim; Alan Giles
Neutrophil elastase cleavage of human factor IX generates an activated factor IX-like product devoid of coagulant function.
Blood 1998;92(4):1287-96.
1998: Alan Giles; Georges-Etienne Rivard; Jerome M Teitel; I Walker
Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy.
Transfusion science 1998;19(2):139-48.
1998: Alan Giles; B Verbruggen; Georges-Etienne Rivard; Jerome M Teitel; I Walker
A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
Thrombosis and haemostasis 1998;79(4):872-5.
1998: Cherie Cameron; Colleen Notley; S Hoyle; L McGlynn; Christine Hough; Seiki Kamisue; Alan Giles; David Lillicrap
The canine factor VIII cDNA and 5' flanking sequence.
Thrombosis and haemostasis 1998;79(2):317-22.
1997: John Samis; M Garrett; R P Manuel; Michael E Nesheim; Alan Giles
Human neutrophil elastase activates human factor V but inactivates thrombin-activated human factor V.
Blood 1997;90(3):1065-74.
1996: Y A Senis; M Richardson; S Tinlin; Donald H Maurice; Alan Giles
Changes in the pattern of distribution of von Willebrand factor in rat aortic endothelial cells following thrombin generation in vivo.
British journal of haematology 1996;93(1):195-203.
1995: Donald H Maurice; Y A Senis; Hanguan Liu; Alan Giles; E H Horn
Cell layer-specific expression of cyclic nucleotide phosphodiesterases in rat arteries: molecular cloning using isolated cell layers from paraformaldehyde-fixed tissues.
Journal of pharmacological and toxicological methods 1995;34(3):175-85.
1994: E Furmaniak-Kazmierczak; T D Cooke; R Manuel; A Scudamore; H Hoogendorn; Alan Giles; Michael E Nesheim
Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage.
The Journal of clinical investigation 1994;94(2):472-80.
1994: M Richardson; S Tinlin; M De Reske; S Webster; Y Senis; Alan Giles
Morphological alterations in endothelial cells associated with the release of von Willebrand factor after thrombin generation in vivo.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1994;14(6):990-9.
1994: Alan Giles
Functional, biochemical, and morphological evaluations of experimental hemophilia therapies in animal models.
Seminars in hematology 1994;31(2 Suppl 4):56-9.
1994: Lesley Mitchell; H Hoogendoorn; Alan Giles; Patricia Vegh; Maureen Andrew
Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency.
Blood 1994;83(2):386-91.
1993: C H Toh; H Hoogendoorn; Alan Giles
The generation of thrombin in vivo induces the selective loss of high molecular weight multimers of von Willebrand factor and the reversible sequestration of platelets.
British journal of haematology 1993;85(4):751-60.
1993: D D Pittman; E M Alderman; K N Tomkinson; J H Wang; Alan Giles; Randal J Kaufman
Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII.
Blood 1993;81(11):2925-35.
1993: M F Scully; C H Toh; H Hoogendoorn; R P Manuel; Michael E Nesheim; S Solymoss; Alan Giles
Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation.
Thrombosis and haemostasis 1993;69(5):448-53.
1993: S Tinlin; S Webster; Alan Giles
The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): a ten-year longitudinal study.
Thrombosis and haemostasis 1993;69(1):21-4.
1992: Fletcher B Taylor; H Hoogendoorn; Alvin C K Chang; Glenn Peer; Michael E Nesheim; R Catlett; D C Stump; Alan Giles
Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C.
Blood 1992;79(7):1720-8.
1992: N i Hong yu; Alan Giles
Normalization of the haemostatic plugs of dogs with haemophilia A (factor VIII deficiency) following the infusion of a combination of factor Xa and phosphatidylcholine/phosphatidylserine vesicles.
Thrombosis and haemostasis 1992;67(2):264-71.
1992: EW Murray; Alan Giles; David Lillicrap
Germ-line mosaicism for a valine-to-methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease.
American journal of human genetics 1992;50(1):199-207.
1991: David Lillicrap; EW Murray; K Benford; V S Blanchette; G E Rivard; R Wensley; Alan Giles
Recurring mutations at CpG dinucleotides in the region of the von Willebrand factor gene encoding the glycoprotein Ib binding domain, in patients with type IIB von Willebrand's disease.
British journal of haematology 1991;79(4):612-7.
1991: H Hoogendoorn; C H Toh; Michael E Nesheim; Alan Giles
Alpha 2-macroglobulin binds and inhibits activated protein C.
Blood 1991;78(9):2283-90.
1991: Michael E Nesheim; D D Pittman; Alan Giles; D N Fass; J H Wang; D Slonosky; Randal J Kaufman
The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets.
The Journal of biological chemistry 1991;266(27):17815-20.
1991: EW Murray; Alan Giles; P J Bridge; I R Peake; David Lillicrap
Cosegregation of von Willebrand factor gene polymorphisms and possible germinal mosaicism in type IIB von Willebrand disease.
Blood 1991;77(7):1476-83.
1990: D C Stump; F B Taylor; Michael E Nesheim; Alan Giles; W H Dzik; E G Bovill
Pathologic fibrinolysis as a cause of clinical bleeding.
Seminars in thrombosis and hemostasis 1990;16(3):260-73.
1990: Alan Giles; Michael E Nesheim; S W Herring; H Hoogendoorn; D C Stump; C M Heldebrant
The fibrinolytic potential of the normal primate following the generation of thrombin in vivo.
Thrombosis and haemostasis 1990;63(3):476-81.
1990: D S Boskovic; Alan Giles; Michael E Nesheim
Studies of the role of factor Va in the factor Xa-catalyzed activation of prothrombin, fragment 1.2-prethrombin-2, and dansyl-L-glutamyl-glycyl-L-arginine-meizothrombin in the absence of phospholipid.
The Journal of biological chemistry 1990;265(18):10497-505.
1990: H Hoogendoorn; Michael E Nesheim; Alan Giles
A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model.
Blood 1990;75(11):2164-71.
1990: David Lillicrap; P J Bridge; Alan Giles
Organization of a hemophilia genetic screening program. Ontario Hemophilia Study Group.
Progress in clinical and biological research 1990;324():19-28.
1989: J Drouin; David Lillicrap; C A Izaguirre; M Sutherland; S Windsor; K Benford; H Hoogendorn; Alan Giles
Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis.
American journal of clinical pathology 1989;92(4):471-8.
1988: Michael E Nesheim; D D Pittman; J H Wang; D Slonosky; Alan Giles; Randal J Kaufman
The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets.
The Journal of biological chemistry 1988;263(31):16467-70.
1988: P Vander Velden; Alan Giles
A detailed morphological evaluation of the evolution of the haemostatic plug in normal, factor VII and factor VIII deficient dogs.
British journal of haematology 1988;70(3):345-55.
1988: David Lillicrap; Jeanette J A Holden; Alan Giles; Bradley N White
Carrier detection strategy in haemophilia A: the benefits of combined DNA marker analysis and coagulation testing in sporadic haemophilic families.
British journal of haematology 1988;70(3):321-6.
1988: Alan Giles; K G Mann; Michael E Nesheim
A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo.
British journal of haematology 1988;69(4):491-7.
1988: Alan Giles; S Tinlin; H Hoogendoorn; M A Fournel; P Ng; N Pancham
In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency).
Blood 1988;72(1):335-9.
1988: S A Taylor; David Lillicrap; Victor Blanchette; Alan Giles; Jeanette J A Holden; Bradley N White
A complete deletion of the factor IX gene and new TaqI variant in a hemophilia B kindred.
Human genetics 1988;79(3):273-6.
1987: Alan Giles
Guidelines for the use of animals in biomedical research.
Thrombosis and haemostasis 1987;58(4):1078-84.
1987: Alan Giles; H Hoogendoorn; K Benford
Type IIB von Willebrand's disease presenting as thrombocytopenia during pregnancy.
British journal of haematology 1987;67(3):349-53.
1987: David Lillicrap; Bradley N White; Jeanette J A Holden; Alan Giles
Carrier detection in the hemophilias.
American journal of hematology 1987;26(3):285-96.
1987: Alan Giles
By what mechanisms could prothrombin complex concentrates promote factor VIII bypassing activity in vivo?
Transfusion medicine reviews 1987;1(2):131-7.
1987: H Grover; M A Phillips; David Lillicrap; Alan Giles; M Bernadette Garvey; Jerome M Teitel; Georges-Etienne Rivard; Victor Blanchette; Bradley N White; Jeanette J A Holden
Carrier detection of haemophilia A using DNA markers in families with an isolated affected male.
Clinical genetics 1987;32(1):10-9.
1987: David Lillicrap; W E Corbett; Alan Giles; A D Ginsburg
Erythroblast multinuclearity in bone marrow and spleen. Congenital dyserythropoietic anemia-like abnormalities without functional evidence of dyserythropoiesis.
Archives of pathology & laboratory medicine 1987;111(6):536-9.
1987: L M Mulligan; H J Grover; V S Blanchette; Alan Giles; D P Lillicrap; A Phillips; Jeanette J A Holden; Bradley N White
Recombination between the factor VIII gene and the DXS52 locus gives the most probable genetic order as centromere-fra(X)-DXS15-DXS52-F8C-telomere.
American journal of medical genetics 1987;26(3):751-60.
1986: D P Lillicrap; P M Ford; Alan Giles
Prolonged thrombocytopenia in post-transfusion purpura (PTP) associated with changes in the crossed immunoelectrophoretic pattern of von Willebrand factor (vWF), circulating immune complexes and endothelial cell cytotoxicity.
British journal of haematology 1986;62(1):37-46.
1985: Alan Giles; S Tinlin; L Brosseau; H Hoogendoorn
In vivo studies of the role of factor VII in hemostasis.
Blood 1985;65(5):1197-200.
1984: Paula B Tracy; Alan Giles; K G Mann; L L Eide; H Hoogendoorn; G E Rivard
Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.
The Journal of clinical investigation 1984;74(4):1221-8.
1984: Alan Giles; H Hoogendoorn; S Tinlin
The thrombogenicity of prothrombin complex concentrates. IV. The source of coagulant-active phospholipid.
Thrombosis research 1984;34(6):567-72.
1984: Alan Giles; P Greenwood; S Tinlin
A platelet release defect induced by aspirin or penicillin G does not increase gastrointestinal blood loss in thrombocytopenic rabbits.
British journal of haematology 1984;57(1):17-23.
1984: Alan Giles; S Tinlin; H Hoogendoorn; P Greenwood; R Greenwood
Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency).
Blood 1984;63(2):451-6.
1982: Alan Giles; S Tinlin; R Greenwood
A canine model of hemophilic (factor VIII:C deficiency) bleeding.
Blood 1982;60(3):727-30.
1982: Alan Giles; Michael E Nesheim; H Hoogendoorn; Paula B Tracy; K G Mann
Stroma free human platelet lysates potentiate the in vivo thrombogenicity of factor Xa by the provision of coagulant-active phospholipid.
British journal of haematology 1982;51(3):457-68.
1982: Alan Giles; Michael E Nesheim; H Hoogendoorn; Paula B Tracy; K G Mann
The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits.
Blood 1982;59(2):401-7.
1981: John G Kelton; D Meltzer; J Moore; Alan Giles; W E Wilson; R Barr; J Hirsh; Peter B Neame; P J Powers; Irwin Walker; F Bianchi; C J Carter
Drug-induced thrombocytopenia is associated with increased binding of IgG to platelets both in vivo and in vitro.
Blood 1981;58(3):524-9.
1981: Alan Giles; H Hoogendoorn; Morris A Blajchman
The thrombogenicity of prothrombin complex concentrates: III. The relationship of in vivo thrombogenicity to the nature of the starting plasma.
Thrombosis research 1981;21(3):255-63.
1980: V P Young; Alan Giles; J Pater; W E Corbett
Sex differences in bleeding time and blood loss in normal subjects following aspirin ingestion.
Thrombosis research 1980;20(5-6):705-9.
1980: J G Kelton; Alan Giles; P B Neame; P Powers; N Hageman; J Hirsch
Comparison of two direct assays for platelet-associated IgG (PAIgG) in assessement of immune and nonimmune thrombocytopenia.
Blood 1980;55(3):424-9.
1980: Alan Giles; H Hoogendoorn; Morris A Blajchman; J Hirsh
The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits.
Thrombosis research 1980;17(3-4):555-60.
1980: Alan Giles; M Johnston; H Hoogendoorn; Morris A Blajchman; J Hirsh
The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits.
Thrombosis research 1980;17(3-4):353-66.